CohBar Inc
OTC:CWBR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
CohBar Inc
OTC:CWBR
|
US |
|
Bunker Hill Mining Corp
OTC:BHLL
|
CA |
|
M
|
Manila Broadcasting Co
XPHS:MBC
|
PH |
|
S
|
Sylvamo Corp
NYSE:SLVM
|
US |
|
Astra Micro Wave Products Ltd
NSE:ASTRAMICRO
|
IN |
|
D
|
DSW Capital PLC
LSE:DSW
|
UK |
|
Gold Mountain Ltd
ASX:GMN
|
AU |
|
Altimmune Inc
NASDAQ:ALT
|
US |
|
G
|
Gap Inc
LSE:0ITS
|
US |
|
Thob Al Aseel Co SJSC
SAU:4012
|
SA |
|
Aeeris Ltd
ASX:AER
|
AU |
|
ARSS Infrastructure Projects Ltd
NSE:ARSSINFRA
|
IN |
|
T
|
TAJ GVK Hotels and Resorts Ltd
NSE:TAJGVK
|
IN |
|
T
|
Thecoo Inc
TSE:4255
|
JP |
|
United Internet AG
XETRA:UTDI
|
DE |
|
National Oxygen Ltd
BSE:507813
|
IN |
|
BTU Metals Corp
XTSX:BTU
|
CA |
CohBar Inc
CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm focuses on developing therapeutics targeting chronic and age-related diseases. The company is advancing a pipeline of peptide analogs through varying stages of development, such as CB5138-3 for idiopathic pulmonary fibrosis (IPF); CB4211 for the treatment of non-alcoholic steatohepatitis (NASH) and obesity; and several preclinical and discovery-stage programs. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing, and optimizing analogs of these natural mitochondrial derived peptides (MDPs), as well as developing and conducting screens to identify and characterize the activities of these peptides are referred to its Mito+ platform. The company is using its Mito+ platform to identify and develop modified versions of natural peptides called analogs, to treat a range of serious conditions, with a focus on chronic diseases involving inflammation and fibrosis.
CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm focuses on developing therapeutics targeting chronic and age-related diseases. The company is advancing a pipeline of peptide analogs through varying stages of development, such as CB5138-3 for idiopathic pulmonary fibrosis (IPF); CB4211 for the treatment of non-alcoholic steatohepatitis (NASH) and obesity; and several preclinical and discovery-stage programs. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing, and optimizing analogs of these natural mitochondrial derived peptides (MDPs), as well as developing and conducting screens to identify and characterize the activities of these peptides are referred to its Mito+ platform. The company is using its Mito+ platform to identify and develop modified versions of natural peptides called analogs, to treat a range of serious conditions, with a focus on chronic diseases involving inflammation and fibrosis.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
